Vimarsana
Biggest News Aggregation in the World

Page 2 - Adv Chronic News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Adv Chronic. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Adv Chronic Today - Breaking & Trending Today

Sponsored | When piles become more than just a nuisance - Vimarsana News

Sponsored | When piles become more than just a nuisance

Piles grading and treatment.

Source: news24.com
Long-Haul COVID and Neurologic Symptoms: What Neurologists Know So Far - Vimarsana News

Long-Haul COVID and Neurologic Symptoms: What Neurologists Know So Far

Neurology experts Drs Lavanya Visvabharathy, Anna Cervantes-Arslanian, and Jonathan Rogers discuss the mild to severe neurologic symptoms of long-haul COVID.

Artizan Biosciences Selects Lead Product Candidate for Inflammatory Bowel Disease Therapeutic Development Program - Vimarsana News

Artizan Biosciences Selects Lead Product Candidate for Inflammatory Bowel Disease Therapeutic Development Program

Artizan Biosciences Selects Lead Product Candidate for Inflammatory Bowel Disease Therapeutic Development Program - read this article along with other careers information, tips and advice on BioSpace

Artizan Biosciences Selects Lead Product Candidate for Inflammatory Bowel Disease Therapeutic ... - Vimarsana News

Artizan Biosciences Selects Lead Product Candidate for Inflammatory Bowel Disease Therapeutic ...

NEW HAVEN, Conn., Jan. 18, 2022 (GLOBE NEWSWIRE) -- Artizan Biosciences, Inc. (“Artizan”), a precision medicine biotechnology company, today announced the selection of its lead product candidate, ARZC-001, for the

Source: kulr8.com
Novartis Pharma AG: Novartis provides an update on Phase III ligelizumab (QGE031) studies in chronic spontaneous urticaria (CSU) - Vimarsana News

Novartis Pharma AG: Novartis provides an update on Phase III ligelizumab (QGE031) studies in chronic spontaneous urticaria (CSU)

Ad hoc announcement pursuant to Art. 53 LR Ligelizumab, a high-affinity anti-IgE antibody, demonstrated superiority compared with placebo at Week 12 in Phase III PEARL 1 and PEARL 2 trials, but not